Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 1;138(2):278-280.
doi: 10.1097/AOG.0000000000004438.

Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood

Malavika Prabhu  1 , Elisabeth A Murphy, Ashley C Sukhu, Jim Yee, Sunidhi Singh, Dorothy Eng, Zhen Zhao, Laura E Riley, Yawei J Yang
Affiliations
Comment

Antibody Response to Coronavirus Disease 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women and Transplacental Passage Into Cord Blood

Malavika Prabhu et al. Obstet Gynecol. .

Abstract

Coronavirus disease 2019 (COVID-19) vaccination in pregnancy induces a robust maternal immune response, with transplacental antibody transfer detectable in cord blood as early as 16 days after the first dose.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure Zhen Zhao received seed instruments and sponsored research from ET Healthcare and sponsored research from Roche. The other authors did not report any potential conflicts of interest.

Figures

Fig. 1.
Fig. 1.. Maternal antibody response to coronavirus disease 2019 (COVID-19) mRNA vaccination. A. Number of women who produced no antibody response, produced an antibody response but did not demonstrate passive immunity to their neonates, or produced an antibody response and also demonstrated passive immunity to their neonates. Time 0 is day of maternal vaccination dose 1. The earliest detection of antibodies in neonates (passive immunity) was at 16 days post–maternal dose 1. The one mother–neonate dyad with no transfer of antibodies to the neonate was at 10.14 weeks from dose 1 and 6 weeks from dose 2. B. Maternal immunoglobulin (Ig)G levels vs weeks elapsed since maternal vaccination dose 1 for women who received only one dose of the vaccine (n=55). Time point 0 is day of vaccination dose 1. C. Maternal IgG levels vs weeks elapsed since maternal vaccination dose 2 for women who received both doses of the vaccine (n=67). Time point 0 is day of vaccination dose 2. All positive serology cutoffs were 1 (dashed line). The relationship between IgG antibody levels and time was studied using analysis of variance with Tukey post hoc. Statistical analysis was performed using R 3.6.3, RStudio 1.1.463. ns, not significant.
Prabhu. COVID-19 Vaccination in Pregnancy. Obstet Gynecol 2021.
Fig. 2.
Fig. 2.. Neonatal antibody response to maternal coronavirus disease 2019 (COVID-19) mRNA vaccination. A. Cord blood immunoglobulin (Ig)G levels vs maternal IgG levels. Grey dots represent neonates born to mothers who received only one dose of the vaccine. All positive serology cutoffs were 1 (dashed gray line). The relationship between maternal and neonatal IgG levels was studied using Pearson correlation analysis and linear regression on log2-scaled serologic values. CIs are represented by shaded region (95% CI 0.80–0.97). Lower and upper prediction intervals are indicated with dotted red lines. B. Placental transfer ratio (neonatal IgG/maternal IgG) vs weeks elapsed since maternal vaccination dose 2 for 65 dyads containing mothers who received both vaccine doses. Time point 0 is day of vaccine dose 2. The relationship between IgG placental transfer ratio (neonatal/maternal) and time was studied using Pearson correlation analysis and linear regression on placental transfer ratio and time elapsed since dose 2 (weeks). CIs are represented by shaded region (95% CI 0.11–0.16). Lower and upper prediction intervals are indicated with dotted blue lines. Statistical analysis was performed using R 3.6.3, RStudio 1.1.463.
Prabhu. COVID-19 Vaccination in Pregnancy. Obstet Gynecol 2021.
See this image and copyright information in PMC

Comment on

References

    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15. doi: 10.1056/nejmoa2034577 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16. doi: 10.1056/nejmoa2035389 - DOI - PMC - PubMed
    1. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. . COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021. doi: 10.1016/j.ajog.2021.03.023 [Epub ahead of print] - DOI - PMC - PubMed
    1. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal COVID-19 vaccination during pregnancy. Am J Obstet Gynecol 2021. doi: 10.1016/j.ajog.2021.03.035 [Epub ahead of print] - DOI - PMC - PubMed
    1. Kubiak JM, Murphy EA, Yee J, Cagino KA, Friedlander RL, Glynn SM, et al. . Severe acute respiratory syndrome coronavirus 2 serology levels in pregnant women and their neonates. Am J Obstet Gynecol 2021. doi: 10.1016/j.ajog.2021.01.016 [Epub ahead of print] - DOI - PMC - PubMed

Publication types